Literature DB >> 31771348

Classifications of diabetic macular edema.

Lee M Jampol1.   

Abstract

Diabetic retinopathy is a major cause worldwide of vision loss from diabetic maculopathy or proliferative retinopathy. Without widely accepted classifications of diabetic retinopathy and diabetic maculopathy, it is difficult to compare results of clinical trials or monitor clinical care. The European School of Advanced Studies in Ophthalmology has developed an international classification of diabetic maculopathy based upon spectral domain optical coherence tomography, which could be helpful for both initial evaluation and subsequent follow-up of diabetic patients in both clinical practice and experimental trials.

Entities:  

Keywords:  Diabetic macular edema; diabetic retinopathy; optical coherence tomography; retina

Mesh:

Year:  2019        PMID: 31771348     DOI: 10.1177/1120672119889532

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  4 in total

1.  Comment on: Real-world outcomes of two-year Conbercept therapy for diabetic macular edema.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Int J Ophthalmol       Date:  2022-04-18       Impact factor: 1.779

2.  Diabetic Retinopathy and Diabetic Macular Edema in People With Early-Onset Diabetes.

Authors:  Nikitha Gurram Reddy; Ramesh Venkatesh; Chaitra Jayadev; Santosh Gopi Krishna Gadde; Sameeksha Agrawal; Pranjal Mishra; Naresh Kumar Yadav; Jay Chhablani
Journal:  Clin Diabetes       Date:  2022-04-15

3.  Retinal and Choroidal Vascular Perfusion and Thickness Measurement in Diabetic Retinopathy Patients by the Swept-Source Optical Coherence Tomography Angiography.

Authors:  Tingting Liu; Wei Lin; Genggeng Shi; Wenqi Wang; Meng Feng; Xiao Xie; Tong Liu; Qingjun Zhou
Journal:  Front Med (Lausanne)       Date:  2022-03-18

4.  Deep Learning Algorithm-Based MRI Image in the Diagnosis of Diabetic Macular Edema.

Authors:  Xiuping Han; Juan Tan; Yumei He
Journal:  Contrast Media Mol Imaging       Date:  2022-03-04       Impact factor: 3.161

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.